Medicare Issues Coverage Determination For Biocept's Target Selector Assay For Breast Cancer

Biocept Inc BIOC received a favorable final Local Coverage Determination expanding Medicare coverage for the use of its Target Selector assay to identify the HER2 biomarker from circulating tumor cells (CTCs). 

• Reimbursement decision expands access to testing used to provide information to guide targeted treatment options for patients with breast cancer.
• This coverage determination was effective July 4.
• The Company also updates other initiatives, including CNSide, its proprietary test for neuro-oncology, and COVID-19 testing volume, which has reached over 450,000 samples.
• Price Action: BIOC shares are up 1.63% at $4.07 during the market session on the last check Wednesday.